Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Janssen Biotech, Inc.
EIR
•Janssen Biotech, Inc.•November 30, 2018

Janssen Biotech, Inc. – FDA EIR, Nov 30, 2018

Record Details

An FDA surveillance inspection of Janssen Research and Development, LLC, located in Spring House, PA, took place from November 26-30, 2018. This inspection was a high-priority review for a New Drug Application (NDA 212018) for erdafitinib, conducted under the Compliance Program Guidance Manual 7348.810 for Sponsors, Contract Research Organizations, and Monitors. While no formal Form FDA-483 (Inspectional Observations) was issued at the conclusion of the inspection, specific concerns were discussed with the company's management. The main issues identified included an initial failure to provide a comprehensive list of all Contract Research Organizations (CROs) involved in the study, leading to a request for an updated vendor list. Furthermore, deviations were noted in the adherence to study protocols concerning dose interruptions and subject withdrawals due to adverse events. One instance involved a subject continuing treatment despite a Grade 3 adverse event, conflicting with the dose modification plan, though it was documented as a protocol deviation. Another discontinuation based on an investigator's cumulative assessment of Grade 1 and 2 adverse events was deemed acceptable but underscored the need for clarity. The primary actions required were the submission of the complete CRO/vendor list and a renewed emphasis on stringent adherence to study protocols, particularly regarding adverse event management and dose modification strategies, to prevent similar deviations in the future.

Company
Janssen Biotech, Inc.
Inspection date
November 30, 2018
Product type
drugs
Office
Philadelphia District Office
People
  • Anastasia Offordile (issuing_officer)
  • Yohann Loriot (investigator)
  • Monica Williams (company_representative)
  • Arlene Siefker-Radtke (investigator)
  • Peter De Porre (company_representative)
View Company Profile

ID · bfbfb079-348c-422b-b82a-739f6507036f

Other documents for Janssen Biotech, Inc.
  • 483 - 2025-07-29July 29, 2025
  • EIR - 2018-03-05March 5, 2018
  • 483 - 2018-03-05March 5, 2018
  • 483 - 2017-05-18May 18, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Janssen Biotech, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.